Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy

A. Mark Fendrick, MD
Department of Internal Medicine, Health Management and Policy, Division of General Medicine, University of Michigan.

Correspondence: A. Mark Fendrick, MD, Associate Professor, Division of General Medicine, Department of Internal Medicine, Health Management and Policy, University of Michigan, 300 North Ingalls Bldg, Rm 7E06, Box 0429, Ann Arbor, MI 48109-0429; e-mail: amfen@umich.edu

The author has indicated that he has been a consultant for Merck, AstraZeneca, and TAP and is on the speakers’ bureaus of Merck and TAP.

A. Mark Fendrick, MD
Department of Internal Medicine, Health Management and Policy, Division of General Medicine, University of Michigan.

Correspondence: A. Mark Fendrick, MD, Associate Professor, Division of General Medicine, Department of Internal Medicine, Health Management and Policy, University of Michigan, 300 North Ingalls Bldg, Rm 7E06, Box 0429, Ann Arbor, MI 48109-0429; e-mail: amfen@umich.edu

The author has indicated that he has been a consultant for Merck, AstraZeneca, and TAP and is on the speakers’ bureaus of Merck and TAP.

A. Mark Fendrick, MD
Department of Internal Medicine, Health Management and Policy, Division of General Medicine, University of Michigan.

Correspondence: A. Mark Fendrick, MD, Associate Professor, Division of General Medicine, Department of Internal Medicine, Health Management and Policy, University of Michigan, 300 North Ingalls Bldg, Rm 7E06, Box 0429, Ann Arbor, MI 48109-0429; e-mail: amfen@umich.edu

The author has indicated that he has been a consultant for Merck, AstraZeneca, and TAP and is on the speakers’ bureaus of Merck and TAP.